$Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines$
Código QR

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines

Abstract There is an unmet medical need for later-line treatment options for patients with metastatic colorectal cancer (mCRC). Considering that, beyond progression, co-treatment with bevacizumab and cytotoxic chemotherapy showed less toxicity and a significant disease control rate, we aimed to eval...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yeong Hak Bang, Jeong Eun Kim, Ji Sung Lee, Sun Young Kim, Kyu-Pyo Kim, Tae Won Kim, Yong Sang Hong
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/90406605d8d147a48bfed13fe0d89c7a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:90406605d8d147a48bfed13fe0d89c7a
record_format	dspace
spelling	oai:doaj.org-article:90406605d8d147a48bfed13fe0d89c7a2021-12-02T18:17:42ZBevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines10.1038/s41598-021-86482-x2045-2322https://doaj.org/article/90406605d8d147a48bfed13fe0d89c7a2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-86482-xhttps://doaj.org/toc/2045-2322Abstract There is an unmet medical need for later-line treatment options for patients with metastatic colorectal cancer (mCRC). Considering that, beyond progression, co-treatment with bevacizumab and cytotoxic chemotherapy showed less toxicity and a significant disease control rate, we aimed to evaluate the efficacy of capecitabine and bevacizumab. This single-center retrospective study included 157 patients between May 2011 and February 2018, who received bevacizumab plus capecitabine as later-line chemotherapy after progressing with irinotecan, oxaliplatin, and fluoropyrimidines. The study treatment consisted of bevacizumab 7.5 mg/kg on day 1 and capecitabine 1,250 mg/m2 orally (PO) twice daily on day 1 to 14, repeated every 3 weeks. The primary endpoint was progression-free survival (PFS). The median PFS was 4.6 months (95% confidence interval [CI] 3.9–5.3). The median overall survival (OS) was 9.7 months (95% CI 8.3–11.1). The overall response rate was 14% (22/157). Patients who had not received prior targeted agents showed better survival outcomes in the multivariable analysis of OS (hazard ratio [HR] = 0.59, 95% CI 0.43–0.82, P = 0.002) and PFS (HR = 0.61, 95% CI 0.43–0.85, P = 0.004). Bevacizumab plus capecitabine could be a considerably efficacious option for patients with mCRC refractory to prior standard treatments.Yeong Hak BangJeong Eun KimJi Sung LeeSun Young KimKyu-Pyo KimTae Won KimYong Sang HongNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yeong Hak Bang Jeong Eun Kim Ji Sung Lee Sun Young Kim Kyu-Pyo Kim Tae Won Kim Yong Sang Hong Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
description	Abstract There is an unmet medical need for later-line treatment options for patients with metastatic colorectal cancer (mCRC). Considering that, beyond progression, co-treatment with bevacizumab and cytotoxic chemotherapy showed less toxicity and a significant disease control rate, we aimed to evaluate the efficacy of capecitabine and bevacizumab. This single-center retrospective study included 157 patients between May 2011 and February 2018, who received bevacizumab plus capecitabine as later-line chemotherapy after progressing with irinotecan, oxaliplatin, and fluoropyrimidines. The study treatment consisted of bevacizumab 7.5 mg/kg on day 1 and capecitabine 1,250 mg/m2 orally (PO) twice daily on day 1 to 14, repeated every 3 weeks. The primary endpoint was progression-free survival (PFS). The median PFS was 4.6 months (95% confidence interval [CI] 3.9–5.3). The median overall survival (OS) was 9.7 months (95% CI 8.3–11.1). The overall response rate was 14% (22/157). Patients who had not received prior targeted agents showed better survival outcomes in the multivariable analysis of OS (hazard ratio [HR] = 0.59, 95% CI 0.43–0.82, P = 0.002) and PFS (HR = 0.61, 95% CI 0.43–0.85, P = 0.004). Bevacizumab plus capecitabine could be a considerably efficacious option for patients with mCRC refractory to prior standard treatments.
format	article
author	Yeong Hak Bang Jeong Eun Kim Ji Sung Lee Sun Young Kim Kyu-Pyo Kim Tae Won Kim Yong Sang Hong
author_facet	Yeong Hak Bang Jeong Eun Kim Ji Sung Lee Sun Young Kim Kyu-Pyo Kim Tae Won Kim Yong Sang Hong
author_sort	Yeong Hak Bang
title	Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
title_short	Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
title_full	Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
title_fullStr	Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
title_full_unstemmed	Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
title_sort	bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/90406605d8d147a48bfed13fe0d89c7a
work_keys_str_mv	AT yeonghakbang bevacizumabpluscapecitabineaslaterlinetreatmentforpatientswithmetastaticcolorectalcancerrefractorytoirinotecanoxaliplatinandfluoropyrimidines AT jeongeunkim bevacizumabpluscapecitabineaslaterlinetreatmentforpatientswithmetastaticcolorectalcancerrefractorytoirinotecanoxaliplatinandfluoropyrimidines AT jisunglee bevacizumabpluscapecitabineaslaterlinetreatmentforpatientswithmetastaticcolorectalcancerrefractorytoirinotecanoxaliplatinandfluoropyrimidines AT sunyoungkim bevacizumabpluscapecitabineaslaterlinetreatmentforpatientswithmetastaticcolorectalcancerrefractorytoirinotecanoxaliplatinandfluoropyrimidines AT kyupyokim bevacizumabpluscapecitabineaslaterlinetreatmentforpatientswithmetastaticcolorectalcancerrefractorytoirinotecanoxaliplatinandfluoropyrimidines AT taewonkim bevacizumabpluscapecitabineaslaterlinetreatmentforpatientswithmetastaticcolorectalcancerrefractorytoirinotecanoxaliplatinandfluoropyrimidines AT yongsanghong bevacizumabpluscapecitabineaslaterlinetreatmentforpatientswithmetastaticcolorectalcancerrefractorytoirinotecanoxaliplatinandfluoropyrimidines
_version_	1718378287791603712

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines

Ejemplares similares